|Bid||0.9420 x 1300|
|Ask||0.9650 x 800|
|Day's range||0.9205 - 0.9784|
|52-week range||0.5500 - 4.8600|
|Beta (5Y monthly)||1.15|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Amyris (AMRS) sees lower sales in its Consumer and Technology Access segments in the first quarter.
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of 0% and 0.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Mativ Holdings (MATV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amyris, Inc. (AMRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amyris (AMRS) and Givaudan collaborate to leverage the former's technological platform for designing, scaling and manufacturing the best-performing bio-fermented ingredients.
Record revenues in the Consumer segment drive Amyris' (AMRS) top line in the fourth quarter.
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -160% and 27.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Synthetic-biology company Amyris (NASDAQ: AMRS) had an absolutely awful day on the stock exchange Wednesday, due to an earnings report that fell well short of expectations. After market hours on Tuesday, Amyris divulged its third-quarter results. Alas, the total fell far short of the average analyst estimate of just under $112 million.
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -109.52% and 36.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Amyris had a good news/bad news Tuesday, with the market deciding that the latter outweighed the former. The good was that three of the specialized biotech company's products will be included in the offerings of Sephora when the big cosmetics retailer launches its U.K. website. While having three out of the undoubtedly many Sephora products on the site isn't considerable and thus won't generate monster sales, being in that selection is indisputably a positive development for Amyris.
Analysts working at Wall Street investment banks have some stocks in mind that have fallen on hard times but still have a chance to succeed. Ginkgo Bioworks (NYSE: DNA) and its mission to do fun stuff with DNA excited early investors in 2021. Unfortunately, the company manages custom-built organisms much better than it handles its cash flows.
This call is being webcast live on the events page of the investor section of the Amyris' website at amyris.com. You may listen to a webcast replay of this call by going to the investor section of Amyris' website. With me on today's call are John Melo, president and chief executive officer; and also Eduardo Alvarez, chief operating officer to support our Q&A session today.
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -50% and 20.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
This basket of infrastructure software, technical instrument, and specialty chemicals stocks looks like a good value.